05 Chikungunya Hills 508

CDC ACIP — Vaccine Advisory Committee

Acip

Slides

4

Download PDF ↗ Live URL (may be dead)

Document text

Next steps for the Chikungunya Vaccines Work GroupNational Center for Emerging and Zoonotic Infectious Diseases
Susan Hills MBBS MTH
CDC Lead , Chikungunya Vaccines Work Group
Arboviral Diseases Branch
Division of Vector -Borne Diseases
Fort Collins, Colorado
ACIP Meeting, June 26, 2024
•Work Group gathering data and will discuss additional important 
considerations including:
-Acceptability and value of vaccine to providers and relevant populations
-Feasibility of administration Consideration of recommendations for use of 
chikungunya vaccine in at -risk U.S. territories 
Plans for development of vaccine recommendations
Populations Live 
attenuated vaccine
Travelers Feb 2024
Laboratory workers Feb 2024
Residents of U.S. territories with risk 
Residents of U.S. states with risk 
Plans for development of vaccine recommendations
Populations Live 
attenuated vaccineVirus -like 
particle vaccine
Travelers Feb 2024 
Laboratory workers Feb 2024 
Residents of U.S. territories with risk  
Residents of U.S. states with risk  